Objective Juvenile SLE (jSLE) is an autoimmune disease characterised by the presence of high levels of autoantibodies, ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Objective Traditional initial treatment regimens for lupus nephritis (LN) used oral glucocorticoids (GC) in starting doses up to 1.0 mg/kg/day prednisone equivalent with or without a preceding ...

Original research: Interplay of NF-κB and PPAR-γ transcription factors in patients with juvenile systemic lupus erythematosus (8 January, 2025) ...

Objective To evaluate the treatment patterns, medication adherence, concomitant corticosteroid use, factors influencing sequence of therapies (SOTs), healthcare resource utilisation (HCRU) and ...

CEST (UTC +2 Amsterdam) 09:00–10:30 hours ...

Objectives Antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPLs) and clinical outcomes of thrombosis and/or obstetric morbidity and is associated with ...

Objective To explore the efficacy of initial treatment of newly diagnosed childhood-onset lupus nephritis (cLN) with combination of belimumab and either cyclophosphamide, mycophenolate mofetil, ...

No HTML tags allowed. Web page addresses and e-mail addresses turn into links automatically. Lines and paragraphs break automatically.

Objective We performed a scoping review of randomised clinical trials (RCTs) assessing pharmacological therapies for the initial management of lupus nephritis (LN), focusing on study design, included ...